Complementary and alternative medicine in cardiovascular disease: A review of biologically based approaches

American Heart Journal

Volumn 147, Issue 3, 2004, Pages 401-411

  Miller, Kelly L ^a   Liebowitz, Richard S ^a   Newby, L Kristin ^a,b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b DUKE CLINICAL RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; AMIODARONE; ANTIEMETIC AGENT; ANTIINFECTIVE AGENT; ANTITHROMBOCYTIC AGENT; CARDIOVASCULAR AGENT; CARNITINE; CRATAEGUS EXTRACT; CYCLOSPORIN; DIGOXIN; DILTIAZEM; GARLIC EXTRACT; GINGER EXTRACT; GINSENG EXTRACT; GUGGULSTERONE; HERBACEOUS AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; KAVA EXTRACT; KETOCONAZOLE; MACROLIDE; POLICOSANOL; PROPRANOLOL DERIVATIVE; PROTEINASE INHIBITOR; SPASMOLYTIC AGENT; TANACETUM PARTHENIUM EXTRACT; UBIDECARENONE; UNINDEXED DRUG; VASOACTIVE AGENT; VERAPAMIL; WARFARIN; PLANT MEDICINAL PRODUCT;

ACUPUNCTURE; ALTERNATIVE MEDICINE; ALZHEIMER DISEASE; ANGINA PECTORIS; ANXIETY DISORDER; ATHEROSCLEROSIS; BLEEDING; BLOOD CLOTTING; CARDIOMYOPATHY; CARDIOVASCULAR DISEASE; CHINESE MEDICINE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CORONARY ARTERY DILATATION; CORONARY ARTERY DISEASE; DEPRESSION; DIET SUPPLEMENTATION; EXERCISE; GASTROINTESTINAL SYMPTOM; HEART ATRIUM FIBRILLATION; HEART MUSCLE; HERBAL MEDICINE; HOMEOPATHY; HUMAN; HYPERTENSION; HYPOCHOLESTEROLEMIA; IMMUNOSUPPRESSIVE TREATMENT; INSOMNIA; LEUKOCYTOSIS; LIVER DISEASE; LIVER TOXICITY; LUNG FIBROSIS; MEDICINAL PLANT; MYOPATHY; PHOTOSENSITIVITY; PRIORITY JOURNAL; REVIEW; THROMBOCYTE FUNCTION; THYROID DISEASE; VITAMIN SUPPLEMENTATION; DRUG INTERACTION; PHYTOTHERAPY;

CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; COMPLEMENTARY THERAPIES; DRUG INTERACTIONS; HUMANS; PHYTOTHERAPY; PLANT PREPARATIONS;

EID: 2342432385     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ahj.2003.10.021     Document Type: Article

References (97)

1. Eisenberg D.M., Kessler R.C., Foster C. Unconventional medicine in the United States. N Engl J Med. 328:1993;246-252
2. Eisenberg D.M., Davis R.B., Ettner S.L., et al. Trends in alternative medicine use in the United States, 1990-1997 results of a follow-up national survey. JAMA. 280:1998;1569-1575
3. Astin J.A. Why patients use alternative medicine results of a national study. JAMA. 279:1998;1548-1553
4. National Center for Complementary and Alternative Medicine. Priorities for research. NCCAM Web site. Available at: http: //nccam.nih.gov/research. Accessed May 19, 2003
5. Heptinstall S., Groenewegen W.A., Spangenberg P., et al. Extracts of feverfew may inhibit platelet behavior via neutralization of sulphydryl groups. J Pharm Pharmacol. 39:1987;459-465
6. Makheja A.N., Bailey J. The active principle in feverfew. Lancet. 2:1981;1054
7. Heptinstall S., White A., Williamson L., et al. Extracts of feverfew inhibit granule secretions in blood platelets and polymorphonuclear leucocytes. Lancet. 1:1985;1071-1074
8. Bordia A. Effect of garlic on human platelet aggregation in vitro. Atherosclerosis. 30:1978;355-360
9. Bordia A., Verma S.K., Srivastava K.C. Effect of garlic on platelet aggregation in humans a study in healthy subjects and patients with coronary artery disease. Prostaglandins Leukotrienes Essential Fatty Acids. 55:1996;201-205
10. Backon J. Ginger inhibition of thromboxane synthetase and stimulation of prostacyclin: relevance for medicine and psychiatry. Med Hypotheses. 20:1986;271-278
11. LeBars P.L., Katz M.M., Berman N. A placebo-controlled, double-blind, randomized trial of an extract of Ginkgo biloba for dementia. JAMA. 278:1997;1327-1332
12. Chung K.F., McCusker M., Page C.P., et al. Effect of ginkgolide mixture in antagonizing skin and platelet responses to platelet activating factor in man. Lancet. 1:1987;248-251
13. Rowin J., Lewis S.L. Spontaneous bilateral subdural hematomas associated with chronic Ginkgo biloba ingestion. Neurology. 46:1996;1775-1776
14. Gilbert G.J. Ginkgo biloba. Neurology. 48:1997;1137
15. Matthews M.K. Jr. Association of Ginkgo biloba with intracerebral hemorrhage. Neurology. 50:1998;1933-1934
16. Vale S. Subarachnoid haemorrhage associated with Ginkgo biloba. Lancet. 352:1998;36
17. Chan T.Y.K. Drug interactions as a cause of overanticoagulation and bleedings in Chinese patients receiving warfarin. Int J Clin Pharmacol Ther. 36:1998;403-405
18. Izzat M.B., Yim A.P.C., El-Zufari M.H. A taste of Chinese medicine! Ann Thorac Surg. 66:1998;941-942
19. Yu C.M., Chan J.C.N., Sanderson J.E. Chinese herbs and warfarin potentiation by 'Danshen'. J Intern Med. 241:1997;337-339
20. Tam L.S., Chan T.Y.K., Leung W.K., et al. Warfarin interactions with Chinese traditional medicines danshen and methyl salicylate medicated oil. Aust N Z J Med. 25:1995;258
21. Janetzky K., Morreale A.P. Probable interactions between warfarin and ginseng. Am J Health Syst Pharm. 54:1997;692-693
22. Henderson L., Yue Q.Y., Bergquist C., et al. St John's wort (Hypericum perforatum) drug interactions and clinical outcomes. Br J Clin Pharm. 54:2002;349-356
23. Miller L.G. Herbal medicinals selected clinical considerations focusing on known or potential drug-herb interactions. Arch Int Med. 158:1998;2200-2211
24. Centers for Disease Control and Prevention. Hepatic toxicity possibly associated with kava-containing products - United States, Germany and Switzerland, 1999-2002. JAMA. 289:2003;36-37
25. Botanical.com. Search of individual herbs and supplements. Available at: http://www.botanical.com. Accessed May 20, 2003
26. Fushimi R., Tachi J., Amino N., et al. Chinese medicine interfering with digoxin immunoassays. Lancet. 1:1989;339
27. Suga T. Chemistry and pharmacology of Chan-su, Taisha. Chin Med J (Engl). 10:(Suppl):1973;762-773
28. McRae S. Elevated serum digoxin levels in a patient taking digoxin and Siberian ginseng. CMAJ. 155:1996;293-295
29. Awang D.V. Siberian ginseng toxicity may be a case of mistaken identity. CMAJ. 155:1996;1237
30. Johne A., Brockmoller J., Bauer S., et al. Pharmacokinetic interaction of digoxin with an herbal extract from St. John's wort (Hypericum perforatum). Clin Pharmacol Ther. 66:1999;338-345
31. Schliche H. Phytotherapy in paediatrics handbook for physicians and pharmacists. 1997;143 Medpharm GmbH Scientific Publishers, Stuttgart, Germany
32. US Food and Drug Administration. FDA warns consumers against dietary supplement products that may contain digitalis mislabeled as plantain. June 12, 1997. Available at: www.fda.gov/foi/warning_letters/m329n.pdf. Accessed June 30, 2003
33. Slifman N.R., Obermeyer W.R., Aloi B.K., et al. Contamination of botanical dietary supplements by Digitalis lanata. N Engl J Med. 339:1998;806-811
34. Hypericum Depression Trial Study Group. Effect of Hypericum perforatum (St John's wort) in major depressive disorder a randomized controlled trial. JAMA. 287:2002;1807-1814
35. Ruschitzka F., Meier P.J., Turina M., et al. Acute heart transplant rejection due to Saint John's wort. Lancet. 355:2000;548-549
36. Pepping J. Coenzyme Q10. Am J Health Syst Pharm. 56:1999;519-520
37. Jellin J.M., Gregory P.J., Batz F., et al. Pharmacist's letter/presciber's letter natural medicine comprehensive database. 5th ed:2003;379-382 Therapeutic Research Faculty, Stockton, Calif
38. Langsjoen P., Langsjoen P., Willis R., et al. Treatment of essential hypertension with coenzyme Q10. Mol Aspects Med. 15:(Suppl):1994;S265-272
39. Combs A.B., Porter T.H., Folkers K. Anticoagulant activity of naphthoquinone analog of vitamin K and an inhibitor of coenzyme Q10-enzyme systems. Res Commun Chem Pathol Pharmacol. 13:1976;109-114
40. Landbo C., Almdal T.P. Interaction between warfarin and coenzyme Q10. Ugeskr Laeger. 160:1998;3226-3227
41. Spigset O. Reduced effect of warfarin caused by ubidecarenone. Lancet. 344:1994;1372-1373
42. Folkers K., Vadhanavikit S., Mortensen S.A. Biochemical rationale and myocardial tissue data on the effective therapy of cardiomyopathy with coenzyme Q10. Proc Natl Acad Sci U S A. 82:1985;901-904
43. Mortensen S.A. Perspectives on therapy of cardiovascular disease with coenzyme Q10 (ubiquinone). Clin Investigator. 71:(Suppl):1993;S116-123
44. Langsjoen P.H., Langsjoen P.H., Folkers K. Long-term efficacy and safety of coenzyme Q10 therapy for idiopathic dilated cardiomyopathy. Am J Cardiol. 65:1990;521-523
45. Morisco C., Trimarco B., Condorelli M. Effect of coenzyme Q10 therapy in patients with congestive cardiac failure a long term multicenter randomized study. Clin Investigator. 71:(Suppl):1993;S134-136
46. Soja A.M., Mortensen S.A. Treatment of CHF with CoQ10 illuminated by meta-analyses of clinical trials. Mol Aspects Med. 18:(Suppl):1997;S159-168
47. Baggio E., Gandini R., Plancher A.C., et al. Italian multicenter study on the safety and efficacy of coenzyme Q10 as adjunctive therapy in heart failure. Mol Aspects Med. 15:(Suppl):1994;S287-294
48. Hofman-Bang C., Rehnqvist N., Swedberg K., et al. Coenzyme Q10 as an adjunctive in the treatment of chronic congestive heart failure. J Card Fail. 1:1995;101-107
49. Watson P.S., Scalia G.M., Galbraith A., et al. Lack of effect of coenzyme Q on left ventricular function in patients with congestive heart failure. J Am Coll Cardiol. 33:1999;1549-1552
50. Khatta M., Alexander B.S., Krichten C.M., et al. The effect of coenzyme Q10 in patients with congestive heart failure. Ann Int Med. 132:2000;636-640
51. Laaksonen R., Ojala J.P., Tikkanen M.J., et al. Serum ubiquinone concentrations after short-and long-term treatment with HMG-CoA reductase inhibitors. Eur J Clin Pharmacol. 46:1994;313-317
52. Watts G.F., Castelluccio C., Rice-Evans C., et al. Plasma coenzyme Q (ubiquinone) concentrations in patients treated with simvastatin. J Clin Pathol. 46:1993;1055-1057
53. Kamikawa T., Kobayashi A., Yamashita T., et al. Effects of coenzyme Q10 on exercise tolerance in chronic stable angina pectoris. Am J Cardiol. 56:1985;247-251
54. Burke B.E., Neuenschwander R., Olson R.D. Randomized, double-blind, placebo-controlled trial of coenzyme Q10 in isolated systolic hypertension. South Med J. 94:2001;1112-1117
55. Digiesi V., Cantini F., Oradei A., et al. Coenzyme Q10 in essential hypertension. Mol Aspects Med. 15:(Suppl):1994;S257-263
56. Gouni-Berthold I., Berthold H.K. Policosanol clinical pharmacology and therapeutic significance of a new lipid-lowering agent. Am Heart J. 143:2002;356-365
57. Mas R. Policosanol. Drugs Future. 25:2000;569-586
58. Menendez R., Fernandez S.I., Del Rio A., et al. Policosanol inhibits cholesterol biosynthesis and enhances low density lipoprotein processing in cultured human fibroblasts. Biol Res. 27:1994;199-203
59. Menendez R., Amor A.M., Gonzalez R.M., et al. Effect of policosanol on the hepatic cholesterol biosynthesis of normocholesterolemic rats. Biol Res. 29:1996;253-257
60. Ortensi G., Gladstein J., Valli H., et al. A comparative study of policosanol versus simvastatin in elderly patients with hypercholesterolemia. Curr Ther Res. 58:1997;390-401
61. Benitez M., Romero C., Mas R., et al. A comparative study of policosanol versus pravastatin in patients with type II hypercholesterolemia. Curr Ther Res. 58:1997;859-867
62. Castano G., Mas R., Arruzazabala M.L., et al. Effects of policosanol and pravastatin on lipid profile, platelet aggregation and endothelemia in older hypercholesterolemic patients. Int J Clin Pharm Res. 19:1999;105-116
63. Crespo N., Illnait J., Mas R., et al. Comparative study of the efficacy and tolerability of policosanol and lovastatin in patients with hypercholesterolemia and noninsulin dependent diabetes mellitus. Int J Clin Pharm Res. 19:1999;117-127
64. Canetti M., Moreira M., Illnait J., et al. One-year study of the effect of policosanol (5 mg twice-a-day) on lipid profile in patients with type II hypercholesterolemia. Adv Ther. 12:1995;245-254
65. Aneiros E., Calderon B., Mas R., et al. Effect of successive dose increases of policosanol on the lipid profile and tolerability of treatment. Curr Ther Res. 54:1993;304-312
66. Crespo N., Alvarez R., Mas R., et al. Effects of policosanol on patients with non-insulin-dependent diabetes mellitus and hypercholesterolemia a pilot study. Curr Ther Res. 58:1997;44-51
67. Arruzazabala M.L., Carbajal D., Mas R., et al. Effects of policosanol on platelet aggregation in rats. Thromb Res. 69:1992;321-327
68. 2. Prostaglandins Leukotrienes Essential Fatty Acids. 49:1993;695-697
69. Carbajal D., Arruzazabala M.L., Mas R., et al. Effect of policosanol on experimental thrombosis models. Prostaglandins Leukotrienes Essential Fatty Acids. 50:1994;249-251
70. Arruzazabala M.L., Valdes S., Mas R., et al. Effect of policosanol successive dose increases on platelet aggregation in healthy volunteers. Pharmacol Res. 34:1996;181-185
71. Valdes S., Arruzazabala M.L., Fernandez L., et al. Effect of policosanol on platelet aggregation in healthy volunteers. Int J Clin Pharm Res. 16:1996;67-72
72. Heber D., Yip I., Ashley J.M., et al. Cholesterol-lowering effects of a proprietary Chinese red-yeast-rice dietary supplement. Am J Clin Nutr. 69:1999;231-236
73. Urizar N.L., Liverman A.B., Dodds D.T., et al. A natural product that lowers cholesterol as an antagonist ligand for FXR. Science. 296:2002;1703-1706
74. Singh R.B., Niaz M.A., Ghosh S. Hypolipidemic and antioxidant effects of Commiphora mukul as an adjunct to dietary therapy in patients with hypercholesterolemia. Cardiovasc Drugs Ther. 8:1994;659-664
75. Dalvi S.S., Nayak V.K., Pohujani S.M., et al. Effect of gugulipid on bioavailability of diltiazem and propranolol. J Assoc Physicians India. 42:1994;454-455
76. Opie L.H. Role of carnitine in fatty acid metabolism of normal and ischemic myocardium. Am Heart J. 97:1979;375-388
77. Shug A.L., Thomsen J.H., Folts J.D., et al. Changes in tissue levels of carnitine and other metabolites during ischaemia and anoxia. Arch Biochem Biophys. 187:1978;25-33
78. Colonna P., Iliceto S. Myocardial infarction and left ventricular remodeling results of the CEDIM trial: Carnitine Ecocardiografia Digitalizzata Infarto Miocardico. Am Heart J. 139:(Suppl):2000;S124-130
79. Liedtke A.J., DeMaison L., Nellis S.H. Effects of L-propionylcarnitine on mechanical recovery during reflow in intact hearts. Am J Physiol. 255:1988;H169-176
80. White H.D., Norris R.M., Brown M.A., et al. Left ventricular end-systolic volume as the major determinant of survival after recovery from myocardial infarction. Circulation. 76:1987;44-51
81. St John Sutton M., Pfeffer M.A., Plappert T., et al. Quantitative two-dimensional echocardiographic measurements are major predictors of adverse cardiovascular events after acute myocardial infarction the protective effects of captopril. Circulation. 89:1994;68-75
82. Iliceto S., Scrutinio D., Bruzzi P., et al. Effects of L-carnitine administration on left ventricular remodeling after acute anterior myocardial infarction the L-Carnitine Ecocardiografia Digitalizzata Infarto Miocardico (CEDIM) Trial. J Am Coll Cardiol. 26:1995;380-387
83. Pfeffer M.A., Braunwald E., Moye L.A., et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction results of the survival and ventricular enlargement trial. N Engl J Med. 327:1992;669-677
84. Feldman A. The role of energy metabolism defects in cardiomyopathy from inborn errors to ischemia: introduction. Am Heart J. 139:(Suppl):2000;S61-62
85. Winter S.C., Buist N.R. Cardiomyopathy in childhood, mitochondrial dysfunction, and the role of L-carnitine. Am Heart J. 139:(Suppl):2000;S63-69
86. Rizos I. Three-year survival of patients with heart failure caused by dilated cardiomyopathy and l-carnitine administration. Am Heart J. 139:2000;S130-133
87. Jeejeebhoy F., Keith M., Freeman M., et al. Nutritional supplementation with Myo Vive repletes essential cardiac myocyte nutrients and reduces left ventricular size in patients with left ventricular dysfunction. Am Heart J. 143:2002;1092-1100
88. 2-verbrauch isolierter herzzellen. Münch Med Wschr. 136:(Suppl):1994;39-46
89. Krzeminski T., Chatterjee S.S. Ischemia and early reperfusion induced arrhythmias beneficial effects of an extract of Crataegus oxyacantha. Pharm Pharmacol Lett. 3:1993;45-48
90. Brixius K., Frank K., Münch G., et al. WS 1442 (Crataegus-Spezial- Extrakt) wirkt am insuffizienten menschlichen Myokard Kontraktionskraft- steigernd. Herz-Kreislauf. 30:1998;28-33
91. +-ATPase. Circulation. 96:(Suppl):1997;729-I
92. Holubarsch C.J., Colucci W.S., Meinertz T., et al. Survival and prognosis investigation of crataegus extract WS 1442 in congestive heart failure (SPICE) rationale, study design and study protocol. Eur J Heart Fail. 2:2000;431-437
93. Wiehmayr T, Ernst E. Die therapeutische Wirksamkeit von Crataegus. Fortschr Med 1996;(1-2):27-9
94. Villarruz MV, Dans A, Tan F. Chelation therapy for atherosclerotic cardiovascular disease: Cochrane Peripheral Vascular Diseases Group Cochrane Database of Systematic Reviews. Issue 4, 2002;CD002785
95. Knudtson M.L., Wyse D.G., Galbraith P.D., et al. Chelation therapy for ischemic heart disease a randomized controlled trial. JAMA. 287:2002;481-486
96. National Center for Complementary and Alternative Medicine. Clinical trials: Trial to Assess Chelation Therapy (TACT). Available at: http://clinicaltrials.gov/show/NCT00044213. Accessed May 19, 2003
97. Brown B.G., Zhao X.Q., Chait A., et al. Simvastatin and niacin, antioxidant vitamins or the combination for the prevention of coronary disease. N Engl J Med. 345:2001;1583-1592